[go: up one dir, main page]

WO2005075508A3 - Molecules stat hyperactives et leur utilisation dans des dosages dans lesquels l'activation genique est utilisee - Google Patents

Molecules stat hyperactives et leur utilisation dans des dosages dans lesquels l'activation genique est utilisee Download PDF

Info

Publication number
WO2005075508A3
WO2005075508A3 PCT/EP2005/001462 EP2005001462W WO2005075508A3 WO 2005075508 A3 WO2005075508 A3 WO 2005075508A3 EP 2005001462 W EP2005001462 W EP 2005001462W WO 2005075508 A3 WO2005075508 A3 WO 2005075508A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat
hyperactive
stat molecules
gene activation
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/001462
Other languages
English (en)
Other versions
WO2005075508A8 (fr
WO2005075508A2 (fr
Inventor
Thomas Meyer
Uwe Vinkemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungsverbund Berlin FVB eV
Original Assignee
Forschungsverbund Berlin FVB eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04077629A external-priority patent/EP1637540A1/fr
Application filed by Forschungsverbund Berlin FVB eV filed Critical Forschungsverbund Berlin FVB eV
Publication of WO2005075508A2 publication Critical patent/WO2005075508A2/fr
Publication of WO2005075508A8 publication Critical patent/WO2005075508A8/fr
Publication of WO2005075508A3 publication Critical patent/WO2005075508A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules Stat mutantes et leur utilisation dans l'activation de l'expression génique, le criblage d'inhibiteurs ou d'activateurs de facteurs de transcription, l'identification de protéines de liaison, la production d'un médicament pour le diagnostic et/ou le traitement de maladies associées à l'activation de l'expression génique ainsi que le ciblage de substances actives. Les molécules Stat apparaissant dans le noyau d'une lignée cellulaire de lymphome T se caractérisent en ce qu'au moins un acide aminé hydrophobe conservé sur la surface du domaine N du type sauvage de Stat est mutant.
PCT/EP2005/001462 2004-02-10 2005-02-10 Molecules stat hyperactives et leur utilisation dans des dosages dans lesquels l'activation genique est utilisee Ceased WO2005075508A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP04090039 2004-02-10
EP04090039.1 2004-02-10
EP04090242 2004-06-18
EP04090242.1 2004-06-18
EP04077629A EP1637540A1 (fr) 2004-09-17 2004-09-17 Des molécules hyperactives de stat et procédés d'essai de l'activation génique
EP04077629.6 2004-09-17

Publications (3)

Publication Number Publication Date
WO2005075508A2 WO2005075508A2 (fr) 2005-08-18
WO2005075508A8 WO2005075508A8 (fr) 2005-10-27
WO2005075508A3 true WO2005075508A3 (fr) 2006-07-20

Family

ID=34841403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001462 Ceased WO2005075508A2 (fr) 2004-02-10 2005-02-10 Molecules stat hyperactives et leur utilisation dans des dosages dans lesquels l'activation genique est utilisee

Country Status (1)

Country Link
WO (1) WO2005075508A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096560A1 (fr) * 2000-05-09 2001-12-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine stat2, et polynucleotide codant ce polypeptide
US20040009571A1 (en) * 1998-01-23 2004-01-15 John Kuriyan Dimerization interface of signal transducer and activator of transcription (STAT) proteins
WO2004048524A2 (fr) * 2002-11-23 2004-06-10 Isis Pharmaceuticals, Inc. Modulation de l'expression de stat2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009571A1 (en) * 1998-01-23 2004-01-15 John Kuriyan Dimerization interface of signal transducer and activator of transcription (STAT) proteins
WO2001096560A1 (fr) * 2000-05-09 2001-12-20 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine humaine stat2, et polynucleotide codant ce polypeptide
WO2004048524A2 (fr) * 2002-11-23 2004-06-10 Isis Pharmaceuticals, Inc. Modulation de l'expression de stat2

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN W ET AL: "Turning off signal transducer and activator of transcription (STAT): The negative regulation of STAT signaling", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 114, no. 3, September 2004 (2004-09-01), pages 476 - 489, XP004660844, ISSN: 0091-6749 *
CHEN XIAOMIN ET AL: "A reinterpretation of the dimerization interface of the N-terminal domains of STATs.", PROTEIN SCIENCE : A PUBLICATION OF THE PROTEIN SOCIETY. FEB 2003, vol. 12, no. 2, February 2003 (2003-02-01), pages 361 - 365, XP002351562, ISSN: 0961-8368 *
HORVATH C M ET AL: "A STAT PROTEIN DOMAIN THAT DETERMINES DNA SEQUENCE RECOGNITION SUGGESTS A NOVEL DNA-BINDING DOMAIN", GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US, vol. 9, no. 8, 15 April 1995 (1995-04-15), pages 984 - 994, XP000617031, ISSN: 0890-9369 *
MARG ANDREAS ET AL: "Nucleocytoplasmic shuttling by nucleoporins Nup153 and Nup214 and CRM1-dependent nuclear export control the subcellular distribution of latent Stat1.", THE JOURNAL OF CELL BIOLOGY. 21 JUN 2004, vol. 165, no. 6, 21 June 2004 (2004-06-21), pages 823 - 833, XP002319835, ISSN: 0021-9525 *
MEYER THOMAS ET AL: "A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 30 APR 2004, vol. 279, no. 18, 30 April 2004 (2004-04-30), pages 18998 - 19007, XP002319833, ISSN: 0021-9258 *
MEYER THOMAS ET AL: "Nucleocytoplasmic shuttling of STAT transcription factors.", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS. DEC 2004, vol. 271, no. 23-24, December 2004 (2004-12-01), pages 4606 - 4612, XP002319838, ISSN: 0014-2956 *
OTA NARUHISA ET AL: "N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation.", NATURE IMMUNOLOGY. FEB 2004, vol. 5, no. 2, February 2004 (2004-02-01), pages 208 - 215, XP002319834, ISSN: 1529-2908 *
STREHLOW I ET AL: "Amino-terminal signal transducer and activator of transcription (STAT) domains regulate nuclear translocation and STAT deactivation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 23 OCT 1998, vol. 273, no. 43, 23 October 1998 (1998-10-23), pages 28049 - 28056, XP002319836, ISSN: 0021-9258 *
ZHANG J J ET AL: "Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 24 DEC 1996, vol. 93, no. 26, 24 December 1996 (1996-12-24), pages 15092 - 15096, XP002319837, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2005075508A8 (fr) 2005-10-27
WO2005075508A2 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
Zou et al. The involvement of ubiquitination machinery in cell cycle regulation and cancer progression
Iwai et al. Linear ubiquitin chains: NF-κB signalling, cell death and beyond
Hanpude et al. Deubiquitinating enzymes in cellular signaling and disease regulation
Butcher et al. Arylamine N-acetyltransferase 1: a novel drug target in cancer development
WO2008047150A3 (fr) Variants de protéine ctla-4
CA2796465C (fr) Genes et proteines servant a la synthese de polycetides aromatiques
CA2851316C (fr) Genes et proteines pour la synthese d'alcanoyl-coa
WO2008054534A3 (fr) Systèmes de criblage utilisant le rtp801
WO2007034221A3 (fr) Pronostic et cible de la therapie de cancer
WO2005087953A3 (fr) Polymorphismes genetiques associes a des maladies coronariennes, procedes de detection et utilisations
WO2006101387A3 (fr) STRUCTURE HYBRIDE ß COMPRENANT DES PROTEINES DE LIAISON AMYLOIDES ET METHODES DE DETECTION DE LA STRUCTURE HYBRIDE ß POUR MODULER LA FORMATION DE FIBRILLES DANS LES STRUCTURES HYBRIDES ß ET MODULER LA TOXICITE INDUITE PAR LA STRUCTURE HYBRIDE ß, ET PROCEDE VISANT A CONTRARIER LA COAGULATION SANGUINE
See et al. Cytoplasmic dynein antagonists with improved potency and isoform selectivity
WO2010010000A3 (fr) Procédé de criblage, procédé de diagnostic et petit acide nucléique destinés au traitement de troubles du système nerveux central
WO2005075508A8 (fr) Molecules stat hyperactives et leur utilisation dans des dosages dans lesquels l'activation genique est utilisee
EP1808493A3 (fr) Substrats et procédés de détermination de l'activité d'enzymes de dé-ubiquitinylation
NO20083387L (no) mRNA spleisevariant av dobbelkortinlignende kinasegen, samt anvendelse av samme for diagnose og terapi av cancere av nevroektodermal opprinnelse
WO2007124157A3 (fr) polymorphismes genetiques associes a la maladie coronarienne, procedes de detection et leurs emplois
WO2006083957A3 (fr) Tat-001 et methodes d'evaluation et de traitement d'un cancer
WO2007121721A3 (fr) Molécules cibles thérapeutiques pour mettre au point de nouveaux médicaments employés dans le cadre de troubles de dégénérescence
WO2007150069A3 (fr) Variantes du gène dpyd et leur utilisation
WO2011109618A3 (fr) Graines de plantes ayant des niveaux de composés de stockage modifiés, constructions apparentées et procédé mettant en oeuvre des gènes qui codent pour des polypeptides à motif oxydoréductase
WO2008125280A3 (fr) Nouvelles molécules modulatrices destinées à un système d'expression régulée amélioré
WO2006026611A3 (fr) Expression genique d'un arn mediee par une transcriptase inverse
WO2004060390A3 (fr) Utilisation d'un inhibiteur specifique du recepteur 5ht2b pour le traitement du cancer
WO2007041513A3 (fr) Activateur membranaire conserve de la calcineurine ('conserved membrane activator of calcineurin' ou cmac), nouvelle proteine et cible therapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 33/2005 UNDER (81) ADD "SM"

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase